Zymeworks Inc. (ZYME) stock analysis
ZYME · Zymeworks Inc.
Latest recorded price: USD 26.45
Sector and industry: Healthcare · Biotechnology
Fiscal 2025 figures: revenue growth -36.4%, free cash flow margin -32.6%, ROIC -14.4%. The model flags 2 risk signals for this company (1 high severity).
Similar companies in Healthcare
- AbCellera Biologics Inc. (ABCL)
- Absci Corporation - Common Stock (ABSI)
- Acadia Pharmaceuticals Inc. (ACAD)
- ADMA Biologics, Inc. (ADMA)
- Agios Pharmaceuticals, Inc. (AGIO)
- Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY)
- AnaptysBio, Inc. - Common Stock (ANAB)
- Arrowhead Pharmaceuticals, Inc. - Common Stock (ARWR)